85 related articles for article (PubMed ID: 10951931)
1. [Which urologic treatment alternatives are there for the hemophiliac patient?].
Benoit G; Lambert T; Blanchet P; Laurian Y; Lasjaunias P; D'Oiron R; Eschwege P; Langloys J; Droupy S; Kriaa F; Jardin A
Prog Urol; 2000 Jun; 10(3):388-96. PubMed ID: 10951931
[TBL] [Abstract][Full Text] [Related]
2. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
3. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
4. New protocol for immune tolerance induction in acquired hemophilia.
Nemes L; Pitlik E
Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
6. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
[TBL] [Abstract][Full Text] [Related]
7. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
8. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects.
Reding MT; Wu H; Krampf M; Okita DK; Diethelm-Okita BM; Christie BA; Key NS; Conti-Fine BM
Thromb Haemost; 2000 Oct; 84(4):643-52. PubMed ID: 11057864
[TBL] [Abstract][Full Text] [Related]
10. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
Mariani G; Kroner B;
Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
[TBL] [Abstract][Full Text] [Related]
11. Acquired hemophilia a in a patient with lumbar disc herniation: a case report and review of the literature.
Li J; Shen H; Hou T; Li M; He S; Zhang H
Spine (Phila Pa 1976); 2009 Apr; 34(8):E305-8. PubMed ID: 19365240
[TBL] [Abstract][Full Text] [Related]
12. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.
Wootla B; Mahendra A; Dimitrov JD; Friboulet A; Borel-Derlon A; Rao DN; Uda T; Borg JY; Bayry J; Kaveri SV; Lacroix-Desmazes S
FEBS Lett; 2009 Aug; 583(15):2565-72. PubMed ID: 19595998
[TBL] [Abstract][Full Text] [Related]
13. Response of hemophilia A with bleeding to fresh dry plasma.
Krutvacho T; Chuansumrit A; Isarangkura P; Pintadit P; Hathirat P; Chiewsilp P
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():169-73. PubMed ID: 7886565
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for hemophilia.
Chuah MK; Collen D; VandenDriessche T
J Gene Med; 2001; 3(1):3-20. PubMed ID: 11269333
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
[TBL] [Abstract][Full Text] [Related]
16. Characterization of human hybridoma clones isolated from hemophilia patients with specificity for different domains of coagulating factor VIII.
Gharagozlou S; Ghods R; Bahrami ZS; Roohi A; Jeddi-Tehrani M; Conti-Fine BM; Sharifian RA; Rabbani H; Shokri F
Hum Antibodies; 2003; 12(3):67-76. PubMed ID: 14646035
[TBL] [Abstract][Full Text] [Related]
17. One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype.
Cid AR; Calabuig M; Cortina V; Casaña P; Haya S; Moret A; Cabrera N; Aznar JA
Haemophilia; 2008 Sep; 14(5):1049-54. PubMed ID: 18540892
[TBL] [Abstract][Full Text] [Related]
18. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A.
Goldenberg NA; Hathaway WE; Jacobson L; McFarland K; Manco-Johnson MJ
Haemophilia; 2006 Nov; 12(6):605-14. PubMed ID: 17083510
[TBL] [Abstract][Full Text] [Related]
19. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
20. [Refractory acquired hemophilia A in which factor VIII inhibitor was not detected at onset and thereafter deteriorated after total hip replacement arthroplasty].
Tanaka H; Yokota A; Onoda M; Uehara T; Terano T
Rinsho Ketsueki; 2008 Nov; 49(11):1548-51. PubMed ID: 19047786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
